Table 1.

In univariate analysis: Prognostic Significance of clinical parameters

Characteristics	Classification	N = 173	5OS (%)	p value	5PFS (%)	p value
Sex	Male	111	56.8	0.128	51.4	0.300
	Female	62	66.1		58.1
Age	<60 years	105	68.9	<0.001	60.0	0.005
	≥60 years	68	47.1		44.1
Primary site	Stomach	101	64.4	0.437	58.4	0.351
	Ileocecal	16	62.5		56.3
	Small intestine	33	57.6		48.5
	Colorectal	23	43.5		9.1
B symptoms	No	103	65.0	0.040	60.2	0.011
	Yes	70	52.9		44.3
Lugano stage	I–II stage	110	71.8	<0.001	64.5	<0.001
	III–IV stage	63	39.7		34.9
Immune subtype	GCB	64	65.6	0.452	62.5	0.107
	nGCB	109	56.9		48.6
IPI	≤2 score	124	73.4	<0.001	66.9	<0.001
	>2 score	49	26.5		20.4
Hb	>11 g/dL	118	66.9	0.009	61.0	0.004
	≤11 g/dL	55	45.5		38.2
ALC	≥1.5 × 109/L	87	73.6	<0.001	67.8	<0.001
	<1.5 × 109/L	86	46.5		39.5
AMC	≤0.5 × 109/L	93	69.9	0.013	63.4	0.011
	>0.5 × 109/L	80	48.8		42.5
PLT	≤250 × 109/L	71	56.3	0.323	50.7	0.353
	>250 × 109/L	102	62.7		55.9
LMR	≥2.5	115	73.0	<0.001	67.8	<0.001
	<2.5	58	34.5		25.9
PLR	≤170	80	68.8	0.011	68.4	0.008
	>170	93	52.7		43.2
LDH	≤240	107	72.0	<0.001	68.2	<0.001
	>240	66	40.9		30.3
β2m	≤2.6	97	77.3	<0.001	71.1	<0.001
	>2.6	76	38.2		31.6
Surgery	No	58	51.7	0.012	44.8	0.008
	Yes	115	64.3		58.3

IPI international prognostic index, Hb hemoglobin, ALC the absolute lymphocyte count, AMC absolute monocyte count, PLT platelet count, LMR lymphocyte–monocyte ratio, PLR platelet–lymphocyte ratio, LDH lactate dehydrogenase, β2m β 2-microglobulin, OS overall survival, PFS progression-free survival